Pruritus And Dry Skin
At 16 weeks, 73% of risankizumab patients achieved PSAI 90 vs. 2% of the placebo patients and sPGA 0/1 was reached by 84% of riskanizumab patients vs. 7% of placebo patients (P<0.001).
The control rate increased with current AD severity and was 53.4% among patients receiving immunosuppressants and 83.4% among patients receiving systemic corticosteroids.
"Dermatologists and primary care physicians should be cognizant of any over-the-counter product that their patients are using," the authors of a JAMA report write.
The authors recommend a systematic and holistic approach to assess patients with severe signs and symptoms of AD and impact on quality of life before systemic therapy.
Researchers assessed the long-term safety results from a multicenter, open-label, 48-week safety study of 517 patients ≥2 years of age with mild to moderate AD who continued crisaborole treatment after completing a 28-day phase 3 pivotal study.
There was a significant difference in the effect of neonatal BCG vaccination between children with atopic predisposition and children without atopic predisposition.
The data indicated 59% of patients given Dupixent weekly with topical corticosteroids and 63% of patients given Dupixent every 2 weeks with topical corticosteroids achieved EASI-75 vs. 30% of patients given placebo with topical corticosteroids (P<0.0001).
EpiCeram contains a balanced ratio of ceramides, free fatty acids, and cholesterol, which are essential lipids for total skin barrier repair; they mimic the lipid concentration found in the skin.
The researchers found that the estimated cumulative incidence of eczema was 30.9 and 28.7% in the control and LGG arms at 2 years of age, respectively.
Researchers used IgE immunoblotting to analyze plasma samples from 179 atopic dermatitis patients for IgE-reactivity to a panel of micro-arrayed house dust mites allergen molecules.
The researchers found that patients' out-of-pocket spending for topical steroids was $333.7 million. There was a 226.5% increase in total annual spending, from $237.6 million to $775.9 million.
Dupixent, a human monoclonal antibody, works by inhibiting the overactive signaling of IL-4 and IL-13 proteins, which are believed to play a major role in the persistent inflammation in atopic dermatitis.
Children with frequent use of emollients generally had higher phthalate metabolite and paraben levels than uncommon users, reaching statistical significance for some LMW phthalates and parabens.
The team found no significant differences between the three groups of children who received topical steroid, emollient, or placebo in terms of Patient Oriented Eczema Measure scores.
Ruzicka, Thomas et al. "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis"
Among patients with eczema, most moisturizers showed some benefit but better results were seen when used with topical active treatment, according to a Cochrane Review.
Tridesilon (desonide) Cream, 0.05%, has been made available by Encore Dermatology. This low-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Daily application of petroleum jelly for the first 6 months of an infant's life can provide effective protection against atopic dermatitis, equating to a cost benefit of $353 per quality-adjusted life year (QALY).
This prescription-only lotion is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.
Alitretinoin treatment aids in normalizing expression of barrier genes and proteins in patients with chronic hand eczema (CHE), according to a study published online in the British Journal of Dermatology.
Topical cowhage provocation and skin prick testing with histamine can diagnose atopic dermatitis (AD), according to a study published online July 29 in Allergy.
Eczema have a serious impact on patients' quality of life and overall health, both physically and mentally, according to a report from the annual American Academy of Dermatology Summer Meeting, held from July 28 to 31 in Boston.
Regeneron and Sanofi announced that the Phase 3 study, LIBERTY AD CHRONOS, met its primary and key secondary endpoints for dupilumab in the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.
Regeneron and Sanofi announced that the two Phase 3 studies, LIBERTY AD SOLO 1 and SOLO 2, evaluating dupilumab for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints.